Cronos Group (TSE:CRON) Stock Price Down 0.3% – Here’s Why

Cronos Group Inc. (TSE:CRON)’s stock price fell 0.3% during mid-day trading on Tuesday . The company traded as low as C$3.92 and last traded at C$3.94. 197,661 shares traded hands during mid-day trading, an increase of 21% from the average daily volume of 163,922 shares. The stock had previously closed at C$3.95.

Wall Street Analyst Weigh In

Separately, TD upped their price target on Cronos Group from C$4.50 to C$5.50 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Cronos Group currently has a consensus rating of “Buy” and an average target price of C$4.75.

Cronos Group Price Performance

The business’s 50 day moving average is C$3.90 and its two-hundred day moving average is C$3.70. The company has a debt-to-equity ratio of 0.12, a quick ratio of 24.01 and a current ratio of 21.87. The firm has a market capitalization of C$1.47 billion, a PE ratio of -188.00, a price-to-earnings-growth ratio of 0.12 and a beta of 1.13.

Cronos Group (TSE:CRON) last posted its earnings results on Monday, May 11th. The company reported C$0.06 earnings per share (EPS) for the quarter. Cronos Group had a negative return on equity of 0.19% and a negative net margin of 1.29%.The firm had revenue of C$62.86 million for the quarter. Equities research analysts anticipate that Cronos Group Inc. will post -0.26 earnings per share for the current fiscal year.

Cronos Group Company Profile

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.